Streetbeat News

Products Services

BTTX

Better Therapeutics, Inc. (NASDAQ:BTTX) has amended its debt facility with Hercules Capital, Inc. to extend the Interest Only period, redeem debt without penalties, and potentially remove the minimum cash covenant. The amendment also allows for debt-to-equity conversion under certain conditions. Additionally, Better Therapeutics is implementing cost-saving measures, including salary reductions, to improve its financial position by $5M through Q1 2024. These steps are taken to support the commercial launch of its FDA-authorized lead product, AspyreRx, for type 2 diabetes treatment.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:50 pm

WAB

Wabtec Corporation and Marinsa International have signed a contract to supply engines for 10 new hybrid tugboats for the Panama Canal Authority. Wabtec will provide two 8L250MDA marine engines for each tugboat, focusing on maximum availability and low life-cycle cost. Financial terms of the deal were not disclosed.

Portfolio Pulse from Charles Gross

November 28, 2023 | 12:42 pm

AAPL

META

Apple Inc.'s (AAPL) new NameDrop feature, introduced in iOS 17.1 and watchOS 10.1, is being misrepresented by police departments in several states, leading to misinformation about its functionality. Contrary to police claims that devices can share contact information by just being in close proximity, NameDrop actually requires devices to be nearly touching and both unlocked, with a prompt for consent. The incorrect information has spread widely on social media, including on Facebook, owned by Meta Platforms Inc. (META).

Portfolio Pulse from Rounak Jain

November 28, 2023 | 12:41 pm

NVCR

Novocure (NASDAQ:NVCR) has announced a restructuring plan aimed at optimizing business operations to support growth and long-term value. The plan is expected to reduce operating expenses by about $60 million, which will help fund future growth priorities without increasing the company's forward operating cash burn. Novocure is concentrating its resources on global commercial infrastructure and preparing for the launch of its product for metastatic non-small cell lung cancer, as well as on research and development programs with high potential.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:34 pm

EVBG

Everbridge, Inc. has been chosen by Dubai to protect its nearly 20 million residents and annual tourists. This selection is part of Dubai's efforts to ensure the safety and security of its population and visitors.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:34 pm

SMX

Shares of SMX surged 50% in premarket trading following the announcement of their plan to launch the world's first Plastic Cycle Token.

Portfolio Pulse from Charles Gross

November 28, 2023 | 12:16 pm

OPK

BioReference Health and Prognos Health have announced a collaboration to enhance precision medicine and testing. This partnership aims to improve patient outcomes by integrating laboratory diagnostics with analytics and technology. The collaboration is expected to leverage BioReference's extensive test menu and Prognos' AI-powered analytics platform to provide insights that can inform treatment decisions. OPKO Health, Inc. (OPK), the parent company of BioReference, may benefit from this partnership through potential growth in its diagnostic services segment.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:16 pm

ATHA

Athira Pharma announced a symposium presentation to highlight preclinical study data of ATH-1105 for Amyotrophic Lateral Sclerosis at the upcoming Motor Neurone Disease Association International Symposium.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:16 pm

CCCC

C4 Therapeutics (CCCC) will host a webcast to present new Phase 1 dose escalation data for relapsed refractory multiple myeloma from their ongoing Phase 1/2 clinical trial of CFT7455 on December 12, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:15 pm

RLYB

Rallybio has released preliminary data from the completed multiple dose cohort of their Phase 1 safety and pharmacokinetics study for RLY212. RLY212 is being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia, a condition that can cause bleeding in the brain and other organs of fetuses and newborns.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:14 pm